GSK increases ownership in Theravance

As reported by Pharmiweb, GSK announced today that they have increased their shares in Theravance, who they have a long standing partnership with.

Theravance’s shareholders have approved the transaction which will see the UK drug major buy 10 million shares priced at $21.29 apiece. This means GSK now owns about 25.8 million shares in  Theravance’s.

The companies have been partners for nearly ten years and have developed Relovair, which combines a once-daily inhaled corticosteroid (fluticasone) with a long-acting beta-agonist (vilanterol). Phase III development has been completed and GSK intends to submit regulatory applications for chronic obstructive pulmonary disease in the USA and Europe in mid-2012.

Click here to see our latest jobs in clincial research

Also click here to see our Clinical Research Nurse jobs at the Salford Lung Study

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in: Industry News, News
CK Logo in place of featured image